[go: up one dir, main page]

PE20011084A1 - Derivados de quinolina como antagonistas alfa-2 - Google Patents

Derivados de quinolina como antagonistas alfa-2

Info

Publication number
PE20011084A1
PE20011084A1 PE2001000208A PE2001000208A PE20011084A1 PE 20011084 A1 PE20011084 A1 PE 20011084A1 PE 2001000208 A PE2001000208 A PE 2001000208A PE 2001000208 A PE2001000208 A PE 2001000208A PE 20011084 A1 PE20011084 A1 PE 20011084A1
Authority
PE
Peru
Prior art keywords
alkyl
antagonists
alpha
alcoxy
halogen
Prior art date
Application number
PE2001000208A
Other languages
English (en)
Inventor
Mia Engstrom
Antti Haapalinna
Siegried Wuster
Jukka Sallinen
Juha-Matti Savola
Lis Hoglund
Original Assignee
Orion Corp
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp, Juvantia Pharma Ltd Oy filed Critical Orion Corp
Publication of PE20011084A1 publication Critical patent/PE20011084A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE QUINOLONA DE FORMULA I ENTRE OTROS DONDE R1 ES H, ALQUILO C1-C6; R2 ES OH, HALOGENO, ALQUILO C1-C6, ALQUILO C1-C6, ALQUENILO C2-C6, ALCOXI C1-C6, HALO-ALQUILO C1-C6, NO2, NH2, ENTRE OTROS; A ES UN ANILLO BENCENO, CICLOALQUILO C5-C7; CUANDO A ES BENCENO CADA R3 ES OH, HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ALCOXI C1-C6, HALO-ALQUILO C1-C6, NO2, NH2; CUANDO A ES CICLOALQUILO C5-C7 CADA R3 ES OH, HALOGENO, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; R4 Y R5 JUNTO A N FORMAN EL GRUPO a DONDE X ES O, =NR6; R6 ES H, OH, NH2, ALQUILO C1-C6, ALQUENILO C2-C6, CN-ALQUILO C1-C6, ENTRE OTROS; Ra Y Rb SON H, OH, HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ALCOXI C1-C6 ENTRE OTROS; m Y t SON 0-3. LOS COMPUESTOS DE FORMULA I SON ANTAGONISTAS DE LOS ADRENOCEPTORES ALFA-2 Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL
PE2001000208A 2000-03-01 2001-03-01 Derivados de quinolina como antagonistas alfa-2 PE20011084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20000480A FI20000480A0 (fi) 2000-03-01 2000-03-01 Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina

Publications (1)

Publication Number Publication Date
PE20011084A1 true PE20011084A1 (es) 2001-10-25

Family

ID=8557801

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000208A PE20011084A1 (es) 2000-03-01 2001-03-01 Derivados de quinolina como antagonistas alfa-2

Country Status (21)

Country Link
EP (1) EP1263733A2 (es)
JP (1) JP2003525274A (es)
KR (1) KR20020089372A (es)
CN (1) CN1468224A (es)
AR (1) AR034249A1 (es)
AU (1) AU2001239331A1 (es)
BR (1) BR0108816A (es)
CA (1) CA2400657A1 (es)
CZ (1) CZ20022880A3 (es)
EE (1) EE200200490A (es)
FI (1) FI20000480A0 (es)
HU (1) HUP0204458A3 (es)
IL (1) IL151093A0 (es)
MX (1) MXPA02008402A (es)
NO (1) NO20024159D0 (es)
PE (1) PE20011084A1 (es)
PL (1) PL357874A1 (es)
RU (1) RU2002125944A (es)
SK (1) SK12332002A3 (es)
WO (1) WO2001064645A2 (es)
ZA (1) ZA200206956B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066604A2 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
RU2361869C2 (ru) * 2002-02-05 2009-07-20 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Новые арил- и гетероарилпиперазины
DE60316672T2 (de) 2002-04-03 2008-07-17 Orion Corp. Polycyclische verbindungen als potente alpha2-adrenoceptor antagonisten
AU2003219199A1 (en) * 2002-04-03 2003-10-13 Orion Corporation Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
CN1304374C (zh) * 2002-04-30 2007-03-14 永进药品工业株式会社 可用做caspase－3抑制剂的喹啉衍生物及其制备方法和药用组合物
WO2004067513A1 (en) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
KR101286569B1 (ko) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 신규 약제
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
EP1968961A2 (en) 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
EP2029553A1 (en) * 2006-05-22 2009-03-04 Janssen Pharmaceutica, N.V. Substituted pyrazinone derivatives for use as a medicine
JP2009537596A (ja) 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ６−（４−シクロプロピルピペリジン−１−イル）−２’−メチル−［３，４’］−ビピリジン及びその医薬としての使用
CN102295606A (zh) 2006-05-29 2011-12-28 高点制药有限责任公司 合成3-（1，3-苯并间二氧杂环戊烯-5-基）-6-（4-环丙基哌嗪-1-基）-哒嗪的方法及其适用的中间体
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
TW201026691A (en) 2008-10-07 2010-07-16 Schering Corp Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
AU2010329847A1 (en) * 2009-12-11 2012-07-26 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
CN103524413B (zh) * 2012-07-04 2016-04-20 江苏先声药物研究有限公司 氢化吖啶衍生物及其应用
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CA2944462A1 (en) 2014-03-31 2015-10-08 MiRx Pharmaceuticals, LLC Novel hdmx inhibitors and their use for cancer treatment
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
CN107337641B (zh) * 2017-07-01 2020-04-28 广东医科大学 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
AU2022341967A1 (en) * 2021-09-07 2024-05-16 Gismo Therapeutics, Inc. Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
BR0108816A (pt) 2002-12-10
HUP0204458A3 (en) 2004-07-28
CZ20022880A3 (cs) 2003-06-18
JP2003525274A (ja) 2003-08-26
PL357874A1 (en) 2004-07-26
SK12332002A3 (sk) 2003-07-01
WO2001064645A2 (en) 2001-09-07
RU2002125944A (ru) 2004-02-27
CN1468224A (zh) 2004-01-14
HUP0204458A2 (hu) 2003-04-28
CA2400657A1 (en) 2001-09-07
MXPA02008402A (es) 2003-10-14
AU2001239331A1 (en) 2001-09-12
IL151093A0 (en) 2003-04-10
AR034249A1 (es) 2004-02-18
NO20024159L (no) 2002-08-30
EE200200490A (et) 2003-12-15
KR20020089372A (ko) 2002-11-29
NO20024159D0 (no) 2002-08-30
ZA200206956B (en) 2003-12-01
FI20000480A0 (fi) 2000-03-01
WO2001064645A3 (en) 2001-12-27
EP1263733A2 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
PE20011084A1 (es) Derivados de quinolina como antagonistas alfa-2
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20021155A1 (es) Derivados de quinolina como antagonistas de neuropeptidos y
AR062209A1 (es) Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos.
PE20120418A1 (es) DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP)
PE20020485A1 (es) Derivados de quinolina y quinazolina como antagonistas del neuropeptido y
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20040081A1 (es) Derivados de quinolina e isoquinolina como inhibidores de la secrecion de citoquinas il-8
PE20090509A1 (es) El uso de derivados de benzamida para el tratamiento de transtornos del snc
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
PE18295A1 (es) Derivado de piperidina
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20050694A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
AR077147A1 (es) Compuestos biciclicos y triciclicos como inhibidores de kat ii
PE20001543A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
PE54294A1 (es) Derivado de 5-aminoalquil-1,4-benzodiazepina
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
PE20040828A1 (es) Benzoxazinonas como modulares de 5-hidroxitriptamina (5-ht)
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal